Baseline patient and disease characteristics according to the frequency of Vγ9Vδ2 T cells
| . | Low Vγ9Vδ2 T cells (≤0.75%/LC) . | High Vγ9Vδ2 T cells (> 0.75%/LC) . | P value . |
|---|---|---|---|
| n = 75 (37.9%) . | n = 123 (62.1%) . | ||
| Age, y | |||
| Median (range) | 56.9 (22.4-80.4) | 54.5 (18.9-81.5) | .058 |
| >60 | 30 (40) | 45 (36.6) | .652 |
| Sex, n (%) | |||
| Male | 38 (50.7) | 71 (57.7) | .378 |
| Female | 37 (49.3) | 52 (42.3) | |
| AML etiology, n (%) | |||
| De novo | 69 (92) | 116 (94.3) | .562 |
| Secondary | 6 (8) | 7 (5.7) | |
| WBC, ×10⁹/L | |||
| Median (range) | 30.2 (0.6-191.3) | 24.6 (1.1-154.9) | .451 |
| >50, n (%) | 23 (31.1) | 33 (26.8) | .423 |
| NA, n (%) | 1 (1.3) | 1 (0.8) | |
| FAB category, n (%) | |||
| M0 | 2 (2.7) | 2 (1.6) | .397 |
| M1 | 15 (20.0) | 31 (25.2) | |
| M2 | 14 (18.7) | 29 (23.6) | |
| M3 | 0 (0) | 0 (0) | |
| M4 | 22 (29.3) | 29 (23.6) | |
| M5 | 16 (21.3) | 19 (15.4) | |
| M6 | 0 (0) | 4 (3.3) | |
| M7 | 0 (0) | 0 (0) | |
| NA | 6 (8.0) | 9 (7.3) | |
| PB blasts, % | |||
| Mean (SD) | 49.5 (31.1) | 50.9 (34.1) | .828 |
| ELN classification, n (%) | |||
| Favorable | 33 (44.0) | 46 (37.4) | .373 |
| Intermediate | 42 (56.0) | 77 (62.6) | |
| CBF mutation, n (%) | 10 (13.3) | 14 (11.4) | .823 |
| CEBPA mutation, n (%) | 7 (13.0) | 13 (13.8) | >.999 |
| NPM1 mutation, n (%) | 37 (56.9) | 55 (51.9) | .532 |
| FLT3 mutation, n (%) | 22 (34.4) | 36 (34.0) | >.999 |
| Vγ9Vδ2 T cells among LC, % | |||
| Mean (SD) | 0.4 (0.2) | 3.9 (5.1) | <.0001 |
| 30-d mortality, n (%) | 1 (1.3) | 2 (1.6) | >.999 |
| 60-d mortality, n (%) | 6 (8.0) | 5 (4.1) | .339 |
| CR after induction, n (%) | 64 (85.3) | 97 (78.9) | .347 |
| HSCT, n (%) | 12 (16.0) | 20 (16.5) | >.999 |
| . | Low Vγ9Vδ2 T cells (≤0.75%/LC) . | High Vγ9Vδ2 T cells (> 0.75%/LC) . | P value . |
|---|---|---|---|
| n = 75 (37.9%) . | n = 123 (62.1%) . | ||
| Age, y | |||
| Median (range) | 56.9 (22.4-80.4) | 54.5 (18.9-81.5) | .058 |
| >60 | 30 (40) | 45 (36.6) | .652 |
| Sex, n (%) | |||
| Male | 38 (50.7) | 71 (57.7) | .378 |
| Female | 37 (49.3) | 52 (42.3) | |
| AML etiology, n (%) | |||
| De novo | 69 (92) | 116 (94.3) | .562 |
| Secondary | 6 (8) | 7 (5.7) | |
| WBC, ×10⁹/L | |||
| Median (range) | 30.2 (0.6-191.3) | 24.6 (1.1-154.9) | .451 |
| >50, n (%) | 23 (31.1) | 33 (26.8) | .423 |
| NA, n (%) | 1 (1.3) | 1 (0.8) | |
| FAB category, n (%) | |||
| M0 | 2 (2.7) | 2 (1.6) | .397 |
| M1 | 15 (20.0) | 31 (25.2) | |
| M2 | 14 (18.7) | 29 (23.6) | |
| M3 | 0 (0) | 0 (0) | |
| M4 | 22 (29.3) | 29 (23.6) | |
| M5 | 16 (21.3) | 19 (15.4) | |
| M6 | 0 (0) | 4 (3.3) | |
| M7 | 0 (0) | 0 (0) | |
| NA | 6 (8.0) | 9 (7.3) | |
| PB blasts, % | |||
| Mean (SD) | 49.5 (31.1) | 50.9 (34.1) | .828 |
| ELN classification, n (%) | |||
| Favorable | 33 (44.0) | 46 (37.4) | .373 |
| Intermediate | 42 (56.0) | 77 (62.6) | |
| CBF mutation, n (%) | 10 (13.3) | 14 (11.4) | .823 |
| CEBPA mutation, n (%) | 7 (13.0) | 13 (13.8) | >.999 |
| NPM1 mutation, n (%) | 37 (56.9) | 55 (51.9) | .532 |
| FLT3 mutation, n (%) | 22 (34.4) | 36 (34.0) | >.999 |
| Vγ9Vδ2 T cells among LC, % | |||
| Mean (SD) | 0.4 (0.2) | 3.9 (5.1) | <.0001 |
| 30-d mortality, n (%) | 1 (1.3) | 2 (1.6) | >.999 |
| 60-d mortality, n (%) | 6 (8.0) | 5 (4.1) | .339 |
| CR after induction, n (%) | 64 (85.3) | 97 (78.9) | .347 |
| HSCT, n (%) | 12 (16.0) | 20 (16.5) | >.999 |
CBF, core-bing factor; CEBPA, CCAAT enhancer binding protein alpha; FAB, French-American-British; FLT3, fms-like tyrosine kinase 3; LC, lymphocyte; NPM1, nucleophosmin 1; WBC, white blood cell; SD, standard deviation.